Epidermolysis bullosa acquisita

Dermatol Online J. 2017 Dec 15;23(12):13030/qt4jk4333w.

Abstract

Epidermolysis bullosa acquisita (EBA) is a rare, acquired subepidermal blistering disease. EBA is characterized by autoantibodies to collagen VII,which serves to link the epidermis to the dermis. The two most common presentations of EBA are classical noninflammatory EBA and bullous pemphigoid-like EBA. Diagnosis of EBA can be challenging as it sharesclinical and histopathologic features with other blistering diseases. Treatment is often recalcitrant and will often necessitate multiple therapies. We presenta case of a thirty-six-year-old Chinese man with EBA and review the literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Autoantibodies / analysis
  • Collagen / immunology
  • Epidermolysis Bullosa Acquisita / drug therapy
  • Epidermolysis Bullosa Acquisita / immunology
  • Epidermolysis Bullosa Acquisita / pathology*
  • Humans
  • Immunologic Factors / therapeutic use
  • Male
  • Prednisone / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • Immunologic Factors
  • Collagen
  • Prednisone